Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low molecular weight heparin for prevention of portal vein thrombosis in acute necrotizing pancreatitis
ChiCTR1900023372Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Nanchang University
- Start
- Jun 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of low molecular weight heparin calcium in necrotizing pancreatitis (ANP) (2 arms), sponsored by First Affiliated Hospital of Nanchang University. Primary endpoint: Incidence of portal vein thrombosis. Planned start Jun 2019; status: not yet recruiting.
02
Drugs
low molecular weight heparin calcium
03
Conditions
necrotizing pancreatitis (ANP)
Beyond the preview
Go deeper on ChiCTR1900023372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023372.